Vol. 3 No. 2 (2023)
Reimbursement Recommendations

Durvalumab (Imfinzi)

Published February 22, 2023

Key Messages

  • CADTH recommends that Imfinzi should be reimbursed by public drug plans for the treatment of locally advanced or metastatic biliary tract cancer (BTC) if certain conditions are met.
  • Imfinzi in combination with gemcitabine plus platinum-based chemotherapy should only be covered to treat patients with locally advanced or metastatic BTC who have not received prior treatment. Patients receiving Imfinzi should be in relatively good health (i.e., have a good performance status, as determined by a specialist).
  • Imfinzi should only be reimbursed when it is used in combination with gemcitabine and platinum-based chemotherapy, if prescribed by specialists with experience in managing BTC, and if the cost of Imfinzi is reduced. Imfinzi should not be reimbursed if it is used to treat patients with Ampulla of Vater (AoV) cancer.